Strate Lisa L, Gralnek Ian M
Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington, USA.
Chief, Institute of Gastroenterology and Hepatology, Ha'Emek Medical Center, Afula, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Am J Gastroenterol. 2016 Apr;111(4):459-74. doi: 10.1038/ajg.2016.41. Epub 2016 Mar 1.
This guideline provides recommendations for the management of patients with acute overt lower gastrointestinal bleeding. Hemodynamic status should be initially assessed with intravascular volume resuscitation started as needed. Risk stratification based on clinical parameters should be performed to help distinguish patients at high- and low-risk of adverse outcomes. Hematochezia associated with hemodynamic instability may be indicative of an upper gastrointestinal (GI) bleeding source and thus warrants an upper endoscopy. In the majority of patients, colonoscopy should be the initial diagnostic procedure and should be performed within 24 h of patient presentation after adequate colon preparation. Endoscopic hemostasis therapy should be provided to patients with high-risk endoscopic stigmata of bleeding including active bleeding, non-bleeding visible vessel, or adherent clot. The endoscopic hemostasis modality used (mechanical, thermal, injection, or combination) is most often guided by the etiology of bleeding, access to the bleeding site, and endoscopist experience with the various hemostasis modalities. Repeat colonoscopy, with endoscopic hemostasis performed if indicated, should be considered for patients with evidence of recurrent bleeding. Radiographic interventions (tagged red blood cell scintigraphy, computed tomographic angiography, and angiography) should be considered in high-risk patients with ongoing bleeding who do not respond adequately to resuscitation and who are unlikely to tolerate bowel preparation and colonoscopy. Strategies to prevent recurrent bleeding should be considered. Nonsteroidal anti-inflammatory drug use should be avoided in patients with a history of acute lower GI bleeding, particularly if secondary to diverticulosis or angioectasia. Patients with established high-risk cardiovascular disease should not stop aspirin therapy (secondary prophylaxis) in the setting of lower GI bleeding. [corrected]. The exact timing depends on the severity of bleeding, perceived adequacy of hemostasis, and the risk of a thromboembolic event. Surgery for the prevention of recurrent lower gastrointestinal bleeding should be individualized, and the source of bleeding should be carefully localized before resection.
本指南为急性显性下消化道出血患者的管理提供了建议。应首先评估血流动力学状态,并根据需要启动血管内容量复苏。应基于临床参数进行风险分层,以帮助区分不良结局风险高和低的患者。伴有血流动力学不稳定的便血可能提示上消化道(GI)出血源,因此需要进行上消化道内镜检查。在大多数患者中,结肠镜检查应作为初始诊断程序,并且应在患者就诊后24小时内,在充分的结肠准备后进行。对于具有高危内镜下出血征象(包括活动性出血、非出血可见血管或附着血凝块)的患者,应给予内镜止血治疗。所使用的内镜止血方式(机械、热凝、注射或联合)通常由出血病因、到达出血部位的途径以及内镜医师对各种止血方式的经验来指导。对于有复发出血证据的患者,应考虑重复结肠镜检查,如有指征则进行内镜止血。对于持续出血且对复苏反应不佳、不太可能耐受肠道准备和结肠镜检查的高危患者,应考虑进行影像学干预(标记红细胞闪烁扫描、计算机断层血管造影术和血管造影术)。应考虑预防复发出血的策略。有急性下消化道出血病史的患者应避免使用非甾体抗炎药,特别是如果出血继发于憩室病或血管扩张。患有已确诊的高危心血管疾病的患者在发生下消化道出血时不应停用阿司匹林治疗(二级预防)。[已修正]确切时机取决于出血的严重程度、止血的充分程度以及血栓栓塞事件的风险。预防复发性下消化道出血的手术应个体化,在切除前应仔细定位出血源。